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Abstract
Background: In this paper we review the evidence of the effect of health interventions on mortality reduction
from hypertensive diseases in pregnancy (HDP). We chose HDP because they represent a major cause of death in
low income countries and evidence of effect on maternal mortality from randomised studies is available for some
interventions.
Methods: We used four approaches to review the evidence of the effect of interventions to prevent or treat HDP
on mortality reduction from HDP. We first reviewed the Cochrane Library to identify systematic reviews and
individual trials of the efficacy of single interventions for the prevention or treatment of HDP. We then searched
the literature for articles quantifying the impact of maternal health interventions on the reduction of maternal
mortality at the population level and describe the approaches used by various authors for interventions related to
HDP. Third, we examined levels of HDP-specific mortality over time or between regions in an attempt to quantify
the actual or potential reduction in mortality from HDP in these regions or over time. Lastly, we compared case
fatality rates in women with HDP-related severe acute maternal morbidity with those reported historically in high
income countries before any effective treatment was available.
Results: The Cochrane review identified 5 effective interventions: routine calcium supplementation in pregnancy,
antiplatelet agents during pregnancy in women at risk of pre-eclampsia, Magnesium sulphate (MgS04) for the
treatment of eclampsia, MgS04 for the treatment of pre-eclampsia, and hypertensive drugs for the treatment of
mild to moderate hypertension in pregnancy.
We found 10 studies quantifying the effect of maternal health interventions on reducing maternal mortality from
HDP, but the heterogeneity in the methods make it difficult to draw uniform conclusions for effectiveness of
interventions at various levels of the health system. Most authors include a health systems dimension aimed at
separating interventions that can be delivered at the primary or health centre level from those that require hospital
treatment, but definitions are rarely provided and there is no consistency in the types of interventions that are
deemed effective at the various levels.
The low levels of HDP related mortality in rural China and Sri Lanka suggest that reductions of 85% or more are
within reach, provided that most women give birth with a health professional who can refer them to higher levels
of care when necessary. Results from studies of severe acute maternal morbidity in Indonesia and Bolivia also
suggest that mortality in women with severe pre-eclampsia or eclampsia in hospital can be reduced by more than
84%, even when the women arrive late.
Conclusions: The increasing emphasis on the rating of the quality of evidence has led to greater reliance on
evidence from randomised controlled trials to estimate the effect of interventions. Yet evidence from randomised
studies is often not available, the effects observed on morbidity may not translate in to mortality, and the
distinction between efficacy and effectiveness may be difficult to make. We suggest that more use should be
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reproduction in any medium, provided the original work is properly cited.made of observational evidence, particularly since such data represent the actual effectiveness of packages of
interventions in various settings.
Introduction
The fifth Millennium Development Goal has set targets
for the reduction of maternal mortality by 2015, but
progress has been slow [1,2]. Effective interventions to
reduce maternal deaths exist but they are often not
available to women in poor countries [3]. Where
resources are limited, information on the costs and
health effects of interventions is thought to be important
to aid decisions on how to reach the MDG-goals [4].
Such information may help to determine what can be
achieved with existing resources, and to decide how
additional funds can be used to maximise the chances
of achieving the MDG-goals [4].
WHO estimates that 88 to 98 percent of maternal
deaths are avoidable with moderate levels of health care
[5]. This deceptively simple statement hides the com-
plexities underlying the assessment of the health effects
of interventions [6]. First, evidence of the efficacy of
interventions needs to be available. In maternal health,
reliable evidence of an effect on maternal mortality is
rarely available and reliance on lower quality evidence –
by current scientific standards - is often necessary [3].
Second, a distinction needs to be made between efficacy
and effectiveness. Effectiveness, taking into account the
coverage and quality of service delivery is thought to be
more representative of the real world, but it requires
robust evidence from a large range of programme set-
tings. Third, interventions act on disease incidence,
severity or mortality, and effect on one outcome does
not easily translate into effect on the other. Lastly, inter-
ventions are generally delivered in packages, and assess-
ments of health effects need to take account of
interactions in the effect between interventions. Infor-
mation on the joint effect of multiple interventions is
rarely available from trials, and assumptions on how
they interact need to be made.
In this paper we review the evidence of the effect of
health interventions on mortality reduction from hyper-
tensive diseases in pregnancy (HDP). We chose HDP
because they represent a major cause of death in low
income countries [7] and evidence of effect on maternal
mortality from randomised studies is available for some
interventions [3]. In our review we first summarise effi-
cacy data from randomised controlled trials, separating
effects on mortality from those on morbidity. We then
review the literature on population models quantifying
the effect of HDP-related maternal health interventions
on mortality and examine the methods used. Lastly, we
explore alternative methods to determine the
effectiveness of comprehensive packages of health inter-
ventions on mortality by examining differentials in
HDP-related mortality and case fatality over time and
between countries or regions.
Methods
We used four approaches to review the evidence of the
effect of interventions to prevent or treat HDP on mor-
tality reduction from HDP. We first reviewed the
Cochrane Library to identify systematic reviews and
individual trials of the efficacy of single interventions for
the prevention or treatment of HDP. We then searched
the literature for articles quantifying the impact of
maternal health interventions on the reduction of
maternal mortality at the population level and describe
the approaches used by various authors for interventions
related to HDP. Third, we examined levels of HDP-
specific mortality over time or between regions in an
attempt to quantify the actual or potential reduction in
mortality from HDP in these regions or over time.
Lastly, we compared case fatality rates in women with
HDP-related severe acute maternal morbidity with those
reported historically in high income countries before
any effective treatment was available.
Cochrane reviews of the efficacy of the prevention or
treatment of HDP on maternal health outcomes
The Cochrane database of Systematic Reviews (June 2010)
was searched using the terms hypertension during preg-
nancy, pre-eclampsia and eclampsia. Reviews were
included if they reported the effect of an intervention on
any of the following HDP-related maternal outcomes:
maternal or HDP-related death, recurring convulsions,
eclampsia, pre-eclampsia, placental abruption, intra- or
postpartum bleeding, and hypertension. Studies from all
countries were considered because few or no data are
available from low-income countries. Reviews with no evi-
dence of effect on any of the HDP-related maternal out-
comes (i.e. confidence intervals on the RR crossed the no-
effect line) were excluded. Reviews with evidence of effect
on at least one of the HDP-related maternal outcomes but
with less than 50 outcome events were also excluded. We
also searched the Cochrane Central Register of Controlled
Trials (June 2010) for trials published from 2000 onwards
using the same search criteria as above. We selected single
interventions for which no Cochrane review had been
performed by June 2010. We followed the standard
recommended steps for data extraction, summary of the
evidence and effect estimates [8].
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prevention or treatment of HDP on mortality from HDP at
the population level
We searched PubMed for articles quantifying the impact of
maternal health interventions on the reduction of maternal
mortality at the population level, using the terms interven-
tions, maternal mortality and effectiveness in our search.
Reference lists from all relevant articles were checked. We
included articles reporting the effect of preventive or cura-
tive interventions on HDP-related mortality, regardless of
the definitions used. Information was extracted on inter-
ventions, the health systems level at which the intervention
was delivered, the mortality outcome, the reported risk
reduction on mortality outcomes, the methods for estimat-
ing effect sizes, and the references quoted.
Comparing current and historic maternal mortality ratios
across regions or countries
To obtain HDP-specific maternal mortality ratios by
region we applied the proportion of deaths from HDP by
region [
7] to region-specific estimates of maternal mortal-
ity for 2005. [9] We also obtained data on the HDP-speci-
fic maternal mortality ratio over time in England & Wales
between 1912 and 2005 [10,11], in Sweden between 1933
and 1975 [12], in Sri Lanka between 1933-200 [13] and in
urban and rural China between 2000 and 2007 [14]. To
estimate the actual or potential risk reduction in mortality
from HDP we compared the levels of maternal mortality
in various regions in 2005 with that in high income coun-
tries in 2005; and the earliest estimates of maternal mor-
tality with the latest estimates. The potential risk
reduction was computed as (earliest [or highest] maternal
mortality ratio – lowest maternal mortality ratio) / earliest
[or highest] maternal mortality ratio).
Comparing current and historic estimates of fatality in
women with SAMM related to HDP
Lastly, we used two recent reviews of severe acute mater-
nal morbidity (SAMM) in high and low income countries
[15,16] and a study from Sweden [12] to identify studies
reporting on SAMM. Studies were selected if they
reported the case fatality rate of HDP, defined as the num-
ber of deaths from HDP divided by the total number of
SAMM from HDP. The potential risk reduction was com-
puted as ((observed case fatality rate – natural case fatality
rate) / observed case fatality rate). The natural case fatality
rate from HDP was estimated from historical data in Eng-
land & Wales (25% [10]) and Sweden (42% [12]).
Results
Cochrane reviews of the efficacy of the prevention or
treatment of HDP on maternal health outcomes
Twenty nine reviews reported the effect of interventions
on HDP-related health outcomes. Eighteen interventions
(reported in 19 reviews) were excluded because there
was no evidence of effect on any of the maternal out-
comes listed. Excluded interventions were supplementa-
tion or prophylactic administration of: antoxidants [17],
zinc [18], Vitamin C [19], Vitamin E [20], pyridoxine
[21], oestrogen [22], progesterone [23], marine oil [24],
garlic [25], diuretics [26], or nitric oxide [27] during
pregnancy. Increased energy and protein intake [28],
altered dietary salt (2 reviews) [29,30] and exercise [31]
during pregnancy were also excluded. Bed rest for
hypertension [32], low dose dopamine for women with
severe pre-eclampsia [33], plasma volume expansion for
treatment of pre-eclampsia [34] or early delivery for
severe pre-eclampsia before 34 weeks gestation [35]
were also not found to be associated with any of the
HDP-related maternal outcomes.
Two further reviews had evidence of effect on at least
one of the HDP-related maternal outcomes, but the
number of events was insufficient to warrant inclusion.
Women with severe hypertension allocated calcium
channel blockers rather than hydralazine were less likely
to have persistent high blood pressure (five trials, RR
0.33 95% CI 0.15-0.70), but the total number of women
with persistent high blood pressure was only 31. [36]
Rest and nutritional supplementation in women at mod-
erate risk of eclampsia reduces the risk of pre-eclampsia
(one trial, RR 0.13 95% CI 0.03-0.51) but only 18
women developed pre-eclampsia in the trial [37].
We read 251 abstracts reported in the Cochrane Cen-
tral Register of Controlled Trials between 2000 and June
2010. Two interventions had evidence of effect on HDP-
related outcomes. One trial assessed the effect of Coen-
zyme Q10 supplementation during pregnancy in women
at increased risk of pre-eclampsia and found a 44%
r e d u c t i o ni np r e - e c l a m p s i a(RR0.56; 95% CI 0.33-0.96)
[38]. Another trial compared induction of labour with
expectant monitoring for gestational hypertension or
mild pre-eclampsia after 36 weeks gestation [39]. No
cases of death or eclampsia were recorded, but women
in the intervention group had a 29% lower risk of a
composite indicator of poor maternal outcome (RR 0.71,
95% CI 0.59-0.86). Poor maternal outcome was defined
as maternal mortality, maternal morbidity (eclampsia,
HELLP syndrome, pulmonary oedema, thromboembolic
disease, or placental abruption), progression to severe
disease (at least one measurement during ante-partum
or post-partum period of systolic blood pressure ≥170
mm Hg, diastolic blood pressure ≥110 mm Hg, or pro-
teinuria ≥5 g per 24 h), and major post-partum haemor-
rhage. These two interventions were not included
because consistency of effect across study populations
could not be assessed.
The results of included reviews are shown in Addi-
tional File 1. We report two prevention strategies:
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antiplatelet agents during pregnancy in women at risk of
pre-eclampsia [41] and three treatment interventions:
Magnesium sulphate (MgS04) for the treatment of
eclampsia (3 reviews) [42-44] MgS04 for the treatment
of pre-eclampsia [45], and hypertensive drugs for the
treatment of mild to moderate hypertension in preg-
nancy [46]. The review documenting the effect of oral
beta-blockers for hypertension [47] is not reported sepa-
rately because beta-blockers are included in a later
review of hypertensive drugs [46]. All studies are rando-
mized controlled trials, and the quality of the trials is
generally high. The number of deaths reported was suf-
ficient in only one review [42] and one review combined
death with severe morbidity to increase the number of
adverse events [40].
There is no doubt that treating women with eclampsia
with MgS04 reduces the risk of maternal death com-
pared to diazepam (RR 0.59 95% CI 0.37-0.94), though
the effect against placebo is not known. MgS04 is also
effective for the treatment of pre-eclampsia: treating
women with pre-eclampsia with MgS04 reduces their
risk of eclampsia (RR 0.41 95% CI 0.29-0.58) and pla-
cental abruption (RR 0.64 95% CI 0.50-0.83), though
there is insufficient evidence to draw conclusions with
regard to the risk of death. The efficacy of the treatment
of hypertension in pregnancy is less clear. Antihyperten-
sive drugs in women with mild to moderate hyperten-
sion do not lower the risk of pre-eclampsia and there
are insufficient numbers of events to assess their effect
on risk of eclampsia or maternal death. Antihypertensive
drugs do halve the risk of developing severe hyperten-
sion (RR 0.50 95% CI 0.41-0.61) [46].
Routine calcium supplementation during pregnancy
halves the risk of pre-eclampsia (RR 0.45 95% CI 0.31-
0.65), and reduces the occurrence of a composite out-
come of death or serious morbidity (RR 0.80 95% CI
0.65-0.97). The reduction in the risk of pre-eclampsia is
greatest for women at high risk of pre-eclampsia (5
trials, 587 women: RR 0.22, 95% CI 0.12-0.42), and for
those with low baseline calcium intake (8 trials, 10,678
women: RR 0.36, 95% CI 0.20-0.65). There is a 17%
reduction in the risk of pre-eclampsia with the use of
antiplatelet agents – mostly low dose aspirin - during
pregnancy in women at risk of pre-eclampsia (RR 0.83
95% CI 0.77-0.89). However, there are no significant dif-
ferences between antiplatelet agents and placebo in the
risk of eclampsia or maternal death.
Population models quantifying the impact of the
prevention or treatment of HDP on mortality from HDP at
the population level
We found 15 studies quantifying the effect of maternal
health interventions on reducing maternal mortality at
the population level, ten of which are included here
(Additional File 2). Five studies were excluded because
they did not report on HDP specifically [48-51] or
because findings were only presented in a chart with no
information on assumptions or the data underlying the
chart [52].
The approach to classifying interventions varies
greatly (Additional File 2). Most authors include a
health systems dimension aimed at separating interven-
tions that can be delivered at the primary or health cen-
tre level from those that require hospital treatment,
though definitions are rarely provided and there is no
consistency in the types of interventions that are
deemed effective at the various levels. At the hospital
level, effective interventions usually consist of MgS04
for the treatment of eclampsia [53-59], and later studies
also include MgS04 for the treatment of pre-eclampsia.
[55,58-60] Caesarean section is generally listed as part
of the hospital package, and Graham et al (2006) [55]
also include calcium supplementation, low dose aspirin,
antioxidants and antihypertensive drugs as effective
interventions at the hospital level.
Primary care interventions tend to focus on screening
and supportive care, with a reliance on referral care for
the management of women at high risk or with compli-
cations. Maine (1991) [61] separates referral to rural
hospitals from referral to urban hospitals, arguing that
rural hospitals are more accessible and therefore more
effective. Four authors report primary care to be effec-
tive in the absence of referral to higher levels of care.
Interventions include sedatives [61], calcium supplemen-
tation [62], or a comprehensive primary care package
including the treatment of hypertension, routine calcium
supplementation, low dose aspirin in high risk women
and MgS04 for the treatment of pre-eclampsia. [60]
Graham et al [54] report that risk screening and man-
a g e m e n ta tt h ef i r s ta i da n db asic obstetric care level
has a substantial effect on reducing mortality from
hypertensive diseases in the absence of referral care,
though the specific interventions deemed to be effective
in managing risk factors at primary care level are not
listed.
HDP-related mortality outcomes range from deaths
due to eclampsia to deaths from eclampsia and pre-
eclampsia or hypertensive disorders of pregnancy. No
definitions are provided.
The approach to estimating effect sizes includes reli-
ance on evidence from expert opinion, previous models,
a single trial or systematic reviews. Four reviews rely on
expert opinion, but the authors do not specify the char-
acteristics or the numbers of experts involved nor how
the expert opinion is arrived at [55]. [56] [57] [61]
W H O( 1 9 9 4 )[ 5 3 ]u s e so n eo fM a i n e ’s early expert opi-
nion-based estimates to calculate the effect of the
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reductions from eclampsia. Interestingly, WHO relies on
the effect estimate for the strategy involving health cen-
tres with referral to rural hospitals rather than the
slightly more conservative estimate for a strategy invol-
ving health centres with referral to urban hospitals. In
later studies, Prata [56] and Graham [55] also use
WHO’s effect estimate as the main source for their
effect sizes.
Seven studies rely on evidence from single trials or
systematic reviews, but the link between the listed inter-
vention, the references quoted and the magnitude of
effect is not always clear. Prata [56] for example, lists
two systematic reviews of the treatment of hypertension
in support of a 48-65% reduction in eclampsia mortality,
even though the review does not show evidence for an
effect of hypertensive treatment on maternal death,
eclampsia or pre-eclampsia. Similarly, Adam et al [57]
report that antenatal screening for pre-eclampsia at the
primary care level is 48% effective in the reduction of
mortality from hypertensive diseases in pregnancy, rely-
ing on expert opinion and the systematic review show-
ing no evidence for an effect of treating hypertension
(Additional File 1). Bhutta et al, on the other hand,
report that the treatment of hypertension reduces
maternal death from HDP by 63%, without a clear refer-
ence to support this statement [60]. Bhutta et al also
report a 30% reduction in mortality from HDP with rou-
tine calcium supplementation in pregnancy, referencing
the review which reports a relative risk of 0.80 for the
combined outcome of death and serious morbidity [60].
Five reviews estimate the reduction of a comprehen-
sive package of hospital care for the management of
pre-eclampsia and eclampsia [54,55,57] [58-60] with
estimates of effect ranging from no added benefit for
caesarean sections [60] to a 76% reduction for a com-
prehensive package [55]. Even though a number of sys-
tematic reviews are quoted, it is not clear how these
estimates are arrived at [57-59]. There are no rando-
mised controlled trials for the combined medical treat-
ment of eclampsia and pre-eclampsia, nor are there any
trials quantifying the effect of a comprehensive package
of obstetric care – including MgS04, labour induction
and caesarean section – on mortality from hypertensive
diseases.
Comparing current and historic maternal mortality ratios
across regions or countries
Table 1 shows HDP-specific maternal mortality by
WHO region, and the risk reduction in mortality from
HDP that can be expected if countries adopted current
models of health care in developed countries. Using this
approach, the risk reducti o ni nm o r t a l i t yf r o mH D P
expected in Africa and Asia is 98.1% and 95.3%
respectively.
Figure 1 shows trends in HDP-specific maternal mor-
tality over time in England & Wales, Sweden, Sri Lanka
and urban and rural China. Definitions of deaths from
HDP are likely to vary between country and over time,
though definitions are rarely provided. In the UK, the
data reported are for puerperal convulsions between
1832 and 1876, toxaemia in 1950, and HDP (eclampsia
and pre-eclampsia) for more recent years [10,11,66].
[10,11,66] The trends in mortality from hypertensive
diseases are remarkably similar in England & Wales and
Sweden. It is interesting to note that both England &
Wales achieved very low levels of mortality from hyper-
tensive diseases in the 1970s, long before MgS04 was
introduced. Urban and rural China and Sri Lanka
achieved equally low levels by the 21
st Century.
Using the levels of mortality reported in England &
Wales in 1912 as the starting point, England & Wales
achieved a fall in mortality from hypertensive diseases of
98.8% while Sweden, Sri Lanka and urban and rural
China achieved reductions of 99.0%, 89.7%, 96.5 and
93.3% respectively. Similarly, using Sweden’sr e p o r t e d
mortality ratios for 1933 as a reference, Sweden
achieved a mortality reduction of 98.6%, while England
& Wales, Sri Lanka and urban and rural China achieved
a reduction of 98.3%, 85.5%, 95.1 and 90.6% respectively.
Comparing current and historic estimates of fatality in
women with SAMM related to HDP
Table 2 shows case fatality rates in women with SAMM
associated with HDP in high income countries. Case
definitions vary, and a detailed discussion is provided
elsewhere
15. The first study shows trends in fatality
rates associated with eclampsia in Sweden from 1861 to
1980. [12] Between 1861 and 1888, at a time when
effective treatment for HDP was unavailable, 42% of
women were thought not to survive an episode of
eclampsia. This proportion fell dramatically in the late
19
th Century when induction of labour was introduced,
and by the late 20
th Century mortality in women with
eclampsia was estimated to be as low as 3.1%. Using the
Swedish estimates of fatality from eclampsia between
1861 and 1980, the risk reduction in mortality from
eclampsia observed in Sweden in this period was 92.6%.
Case fatality rates in women with SAMM from HDP
in contemporary high income countries are very low,
ranging from no deaths in most regions to 1.8% in the
UK in 1992 and the Netherlands between 2004 and
2006. This suggests an effectiveness of the current treat-
ment of SAMM from HDP to be at least 93 to 96%
(using 25% and 42% as natural case fatality rates
respectively).
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SAMM associated with HDP in low income countries.
A detailed discussion of variation in case definitions is
provided elsewhere [16]. Case fatality rates in women
hospitalised with a SAMM from HDP range from 0.5%
in hospitals in Bolivia to 20.8% in hospitals in South
Africa. Using the “natural” case fatality rate in women
with eclampsia reported for Sweden (42%) and England
& Wales (25%), we report a minimum and maximum
estimate of effectiveness of the existing treatment of
severe cases of HDP in the various hospitals. Lower
bound estimates range from 16.7% in hospitals in South
Africa to 98.0% in hospitals in Bolivia. Similarly, higher
bound estimates range from 50.4% in South Africa to
98.8% in Bolivia.
Intervention effects for the Lives Saved Tool (LiST) model
Our recommended estimates for the LiST model are
shown in Table 4. Where evidence from systematic
reviews was available we used the judgement rules pro-
posed by Walker et al [5]. Where no such evidence was
available we relied on our estimates of effect from com-
parisons of case fatality rates in SAMM from HDP in
countries with the lowest case fatality rates (Indonesia
and Bolivia) and from historical trends in HDP mortality
in China, Sri Lanka, Sweden and England and Wales.
Discussion
This study highlights the complexity in quantifying the
effect of interventions to prevent or treat HDP on mortal-
ity from HDP. First, evidence based on the accepted scien-
tific standard - randomised controlled trials - is only
available for a small number of single interventions, and
no randomised trial evidence is available for interventions
which have been highly effective in reducing HDP-related
mortality in high income countries, such as caesarean sec-
tions. Second, only one intervention (MgS04 for eclamp-
sia) has been shown to have an effect on mortality. Third,
the magnitude of effect on severe outcomes is not always
consistent with that seen in less severe outcomes (e.g. Cal-
cium supplementation reduces death/serious morbidity by
20% and pre-eclampsia by 52%). Fourth, estimates of effec-
tiveness of comprehensive intervention packages –
whether extrapolated from trends in HDP mortality over
time or between regions, or from case fatality rates from
SAMM due to HDP in high and low income countries –
vary greatly, and interpretation is hampered by lack of
knowledge on the content of these intervention packages.
Existing models have tried to circumvent these problems
by seeking advice from “experts” and/or by narrowly
focusing on the efficacy of single interventions, but the
inconsistencies, ambiguity and lack of transparency in the
assumptions underlying the models call into question the
validity of reported effect estimates.
The 98% fall in HDP related mortality in the UK and
Sweden over fifty years suggests that HDP-related
deaths are highly avoidable. The fall in mortality from
HDP has been largely attributed to a reduction in the
number of cases of eclampsia, while the incidence of
pre-eclampsia has been more resistant to change
[10,67]. The package of interventions that has caused
this drop is not known with certainty, but antenatal
screening for high blood pressure and proteinuria in the
second half of pregnancy, with early delivery through
induction of labour or caesarean delivery in women
diagnosed with pre-eclampsia is thought to be the main
reason [10]. Induction of labour after 36 weeks gestation
in women with gestational hypertension or mild pre-
eclampsia is clearly effective in reducing adverse mater-
nal outcomes [39]. Optimal timing of delivery before
Table 1 Effect of prevention and treatment of HDP on maternal mortality from HDP comparing hypertensive disease
mortality in 2005 in developed countries with WHO region hypertensive disease mortality in 2005
Africa
(2005)
Asia
(2005)
Latin America and the
Caribbean (2005)
Developed countries
(2005)
Maternal deaths per 100,000 live births [7,9] 820 330 130 9.0
Hypertensive disease deaths per 100,000 live births (%) 74.6 (9.1%) 30.0
(9.1%)
33.4 (25.7%) 1.4 (16.1%)
Mortality reduction assuming developed country models in
2005 as optimal
a
98.1% 95.3% 95.8.5% NA
aMortality reduction was calculated as (Regional maternal mortality ratio (MMR) – MMR in developed countries)/ Regional MMR).
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Figure 1 Trends in mortality from HDP in England & Wales,
Sweden, Sri Lanka and urban and rural China.
Ronsmans and Campbell BMC Public Health 2011, 11(Suppl 3):S8
http://www.biomedcentral.com/1471-2458/11/S3/S8
Page 6 of 1132-34 weeks in women with pre-eclampsia remains a
dilemma because of the uncertain balance between
protecting the mother (by ending pregnancy) and
enhancing the maturity of the baby (by delaying deliv-
ery) [30,80]. After 34 weeks gestation, however, the sur-
vival of babies in high income countries is nearly 100%
and ending the pregnancy by delivering the baby and
the placenta is highly effective [10]. The routine intro-
duction of MgS04 for the treatment of pre-eclampsia
and eclampsia in more recent years is likely to have
further reduced mortality, explaining the very low case
fatality rates seen in women with SAMM from HDP in
high income countries today.
Can these findings be applied to low income countries?
The low levels of HDP related mortality in rural China
and Sri Lanka suggest that reductions of 85% or more are
within reach, provided that most women give birth with a
health professional who can refer them to higher levels of
care when necessary. Results from SAMM studies in Indo-
nesia and Bolivia also suggest that mortality in women
with severe pre-eclampsia or eclampsia in hospital can be
reduced by more than 84%, even when the women arrive
late [78,79]. The high variability in case fatalities for
SAMM from HDP does not necessarily call into question
the potential effectiveness of a tertiary prevention strategy
for HDP. It reflects the reality of poor quality of care in
some settings, including limited availability of essential
drugs, poor adherence to standard guidelines, and huge
delays in receiving emergency care [81]. The availability
and use of MgS04 remains poor, even though the drug is
cheap and has appeared on the WHO’s essential medi-
cines list since 1996 [82]. Secondary prevention of HDP,
with screening for hypertension and proteinuria should
also be possible, but organising referral care once pro-
blems occur remains a huge challenge [83].
Various authors have attempted to identify interven-
tions that can be delivered at health centre level in the
absence of referral care, but the range of interventions
varies greatly. Dietary supplementation with at least 1 g
of calcium a day reduces the risk of death or serious mor-
bidity from HDP by 20%, and the effect may be stronger
for high risk women or those with low dietary calcium.
Calcium is cheap and it should be possible to achieve
high coverage antenatally thro u g hah e a l t hc e n t r ed e l i v -
ery strategy, though the intervention should be started
early in pregnancy. Other interventions are not likely to
work at the health centre level alone. Low dose aspirin
reduces the risk of pre-eclampsia by 17%, but there is no
evidence of an effect on eclampsia or death. Antihyper-
tensive drugs in mild to moderate hypertension during
pregnancy halve the risk of severe hypertension, but they
do not prevent or delay progression to pre-eclampsia or
Table 2 Effect of treatment of HDP on maternal mortality from HDP using severe acute maternal morbidity (SAMM)
case fatality rates in high income countries
Author, year Study population (year) HDP-related conditions Case fatality rate
(Number of deaths/
cases)
Mortality
reduction
a
Natural case
fatality
25% 42%
Hogberg 1985 [12] Sweden (1861-1880) Eclampsia 42.0 - -
Sweden (1881-1900) Eclampsia 20.0 20.0% 52.4%
Sweden (1951-1955) Eclampsia 13.9 44.4% 66.9%
Sweden (1971-1980) Eclampsia 3.1 87.6% 92.6%
Douglas et al 1994 [67] UK (1992) Eclampsia 1.8% (7/382) 92.7% 95.6%
Waterstone et al
2001 [68]
South East Thames Region
(1997-1998)
Severe pre-eclampsia, eclampsia and HELLP
syndrome
0.4% (1/224) 98.2% 98.9%
Zhang et al 2005 [69] Upper Austria (1996-1997) evere pre-eclampsia, eclampsia and HELLP
syndrome
0.0% (0/32) 100.0% 100.0%
Brussels, Belgium (1996) 0.0% (0/115) 100.0% 100.0%
Finland, 65% of deliveries (1996) 0.0% (0/86) 100.0% 100.0%
Four regions in France (1995) 0.4% (1/241) 98.3% 99.0%
Upper Danube, Hungary (1995) 0.0% (0/81) 100.0% 100.0%
Cork, Ireland (1996) 0.0% (0/9) 100.0% 100.0%
Puglia, Italy (1996-1997) 0.0% (0/19) 100.0% 100.0%
Oslo, Norway (1995) 0.0% (0/6) 100.0% 100.0%
Wen et al 2005 [70] Canada (1991-1992) Eclampsia 0.4% (4/973) 98.4% 99.0%
Knight et al 2007 [71] UK (2005-2006) Eclampsia 0.0% (0/214) 100.0% 100.0%
Zwart et al 2008 [72] The Netherlands (2004-2006) Eclampsia and HELLP syndrome 1.8% (4/222) 92.8% 95.7%
aMortality reduction was calculated as (Natural case fatality rate – SAMM fatality rate / Natural case fatality rate).
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essential, but the choice of drug is not obvious, and an
experienced clinician needs to decide on a case by case
basis [46]. MgS04 has been suggested for use at the pri-
mary care level, but MgS04 is difficult to administer, and
health centres need to refer women to hospital, even if
they are able to give a loading those.
Table 4 suggests potential effect estimates for the reduc-
tion of HDP related mortality based on this review. We
postulate that health centres without access to referral care
can contribute to a 20% reduction in death from HDP
through supplementation of pregnant women with cal-
cium, but there is little scope for further reductions unless
referral care is available. If women have access to a hospital
Table 3 Effect of treatment of HDP on maternal mortality from HDP using severe acute maternal morbidity case
fatality rates in low income countries
Author, year Study population
(period)
Definition of HDP-related SAMM Case fatality rate
(Number of
deaths/cases)
Mortality
reduction
a
Natural case
fatality
25% 42%
Mantel et al, 1998 [73] Kalafong and Pretoria
hospitals, South Africa
(1996-1998)
Hypertension with organ failure 20.8% (10/48) 16.7% 50.4%
Khosla et al 2000 [74] One hospital, Rohtak, India
(1998)
Eclampsia 17.7% (11/62) 29.0% 57.8%
Pattinson et al, 2003
[75]
Three regions, South Africa
(year not stated)
Hypertension with organ failure 20.7% (30/145) 17.2% 50.7%
Kaye et al 2003 [76] Mulago hospital, Uganda
(2000)
Eclampsia/pre-eclampsia with organ failure 14.3% (3/21) 42.9% 66.0%
Oladapo et al 2007
[77]
Olabisi Onabanjo hospital,
southwest Nigeria (2002-
2004)
Eclampsia and severe pre-eclampsia with clinical/
laboratory indications for termination of pregnancy to
save the woman’s live
14.9% (21/141) 40.4% 64.5%
Adisasmita et al 2008
[78]
Four hospitals in West-Java,
Indonesia (2003-2004)
Eclampsia and pre-eclampsia with organ failure 3.9% (22/563) 84.4% 90.7%
Roost et al 2009 [79] Four public hospitals in La
Paz and El Alto, Bolivia
(2006-2007)
Eclampsia and pre-eclampsia based on clinical and
management criteria
0.5% (1/184) 98.0% 98.8%
aMortality reduction was calculated as (Natural case fatality rate – SAMM fatality rate / Natural case fatality rate).
Table 4 Potential effect of prevention and treatment of HDP on maternal mortality from HDP using evidence from
systematic reviews, historical trends and fatality rates in SAMM from HDP
Health system level
at which
intervention is
delivered
Intervention Risk reduction
on HDP-
related
mortality
Source of effectiveness estimate
Health centre Calcium supplementation during pregnancy 20% Systematic review of effect of routine calcium
supplementation versus placebo on death/serious
morbidity [40]
(L)District or
secondary hospital
Calcium supplementation during pregnancy 20% Systematic review of effect of routine calcium
supplementation versus placebo on death/serious
morbidity [40]
MgS04 for pre-eclampsia 59% Systematic review of effect of MgS04 versus
placebo for treatment of pre-eclampsia on
eclampsia [45]
MgS04 for eclampsia 41% Systematic review of effect of MgS04 versus
diazepam for treatment of eclampsia on death
[42]
Antenatal screening for hypertension and proteinuria
and treatment of pre-eclampsia and eclampsia with
MgS04 and early delivery in women with severe pre-
eclampsia and eclampsia
84-99% Case fatality rates in SAMM from HDP in
Indonesia [78] and Bolivia [79] and historical
trends in HDP mortality in China and Sri Lanka
Tertiary hospital All the above plus treatment of severe hypertension in
pregnancy and referral to specialist intensive care for
women with severe complications
99% Historical trends in HDP mortality in Sweden and
England & Wales
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Page 8 of 11with qualified staff and drugs, much greater reductions can
be expected. A package of interventions including the
detection of hypertension and proteinuria in pregnancy
and treatment of pre-eclampsia and eclampsia with MgS04
and early delivery can probably reduce HDP mortality by
at least 84%, as was seen in Indonesia and China. Further
reductions require treatment for severe hypertension and
referral to specialist intensive care for women with severe
complications, as is offered in the UK [67].
We have based our estimates of the effect of packages of
interventions on observational data, comparing current
HDP mortality or case fatality with that at times when no
effective interventions were available. This approach has a
number of limitations. First, we assume that variation in
the incidence of HDP mortality or case fatality is entirely
due to health service factors, while there is no biological
or genetic variation between populations. This is clearly
not true. The incidence of HDP varies by parity and
maternal age, and variation in the demographic profile of
the population will affect the incidence and mortality from
HDP. Second, maternal mortality and SAMM are difficult
to measure [2,15,16] and variations in case definitions may
have affected the results. Eclampsia may be one of the
more easily recognised clinical entities, however, and
errors less marked than for other obstetric problems.
Third, unlike SAMM from other diseases which have a
case fatality rate close to 100% if untreated, women can
survive eclampsia in the absence of treatment. We used
historical data from the UK and Sweden to estimate the
natural case fatality rate but such data are clearly impre-
cise, and results have to be interpreted with caution.
The increasing emphasis on the rating of the quality
of evidence has led to greater reliance on evidence from
randomised controlled trials to estimate the effect of
interventions. Yet evidence from randomised studies is
often not available, the effects observed on morbidity
may not translate in to mortality, and the distinction
between efficacy and effectiveness may be difficult to
make. We suggest that more use should be made of
observational evidence, particularly since such data
represent the actual effectiveness of packages of inter-
ventions in various settings.
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